Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31961
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbtahi, Shahab-
dc.contributor.authorBurden, Andrea M.-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorvan Staa, Tjeerd-
dc.contributor.authorVAN DEN BERGH, Joop-
dc.contributor.authorde Vries, Frank-
dc.date.accessioned2020-09-24T12:04:20Z-
dc.date.available2020-09-24T12:04:20Z-
dc.date.issued2020-
dc.date.submitted2020-09-01T13:28:56Z-
dc.identifier.citationJournal of the American Medical Directors Association, 21 (6) , p. 811 -816-
dc.identifier.issn1525-8610-
dc.identifier.urihttp://hdl.handle.net/1942/31961-
dc.description.abstractBisphosphonates (BPs) might have extra benefits in reducing mortality because of their anti-atherosclerotic effects, but studies reported conflicting results. We investigated the association between oral BP use and mortality risk following a major osteoporotic fracture (MOF) in the United Kingdom.-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.rights2019 AMDA - The Society for Post-Acute and Long-Term Care Medicine.-
dc.subject.otherIntima-Media Thickness-
dc.subject.otherHip Fracture-
dc.subject.otherZoledronic Acid-
dc.subject.otherAlendronate-
dc.subject.otherDisease-
dc.subject.otherWomen-
dc.subject.otherCalcification-
dc.subject.otherMetaanalysis-
dc.subject.otherPrevention-
dc.subject.otherMen-
dc.titleThe Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study-
dc.typeJournal Contribution-
dc.identifier.epage816-
dc.identifier.issue6-
dc.identifier.spage811-
dc.identifier.volume21-
local.format.pages6-
local.bibliographicCitation.jcatA1-
dc.description.notesde Vries, F (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.-
dc.description.notesf.devries@uu.nl-
dc.description.otherde Vries, F (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands. f.devries@uu.nl-
local.publisher.placeSTE 800, 230 PARK AVE, NEW YORK, NY 10169 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.jamda.2019.11.003-
dc.identifier.pmid31839557-
dc.identifier.isiWOS:000542142700017-
dc.contributor.orcidvan den Bergh, Joop/0000-0003-3984-2232; Abtahi,-
dc.contributor.orcidShahab/0000-0003-0482-5563; /0000-0001-7082-8530; de Vries,-
dc.contributor.orcidFrank/0000-0003-3837-8319-
dc.identifier.eissn1538-9375-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; de Vries, Frank] Maastricht Univ, Dept Clin Pharm & Toxicol, Med Ctr, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; de Vries, Frank] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; Geusens, Piet] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands.-
local.description.affiliation[Abtahi, Shahab; Burden, Andrea M.; van Staa, Tjeerd; de Vries, Frank] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.-
local.description.affiliation[Burden, Andrea M.] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, Zurich, Switzerland.-
local.description.affiliation[van den Bergh, Joop P.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, Maastricht, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] VieCuri Med Ctr, Dept Internal Med, Venlo, Netherlands.-
local.description.affiliation[van den Bergh, Joop P.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.-
local.description.affiliation[van Staa, Tjeerd] Univ Manchester, Div Informat Imaging & Data Sci, Manchester Acad Hlth Sci Ctr, Sch Hlth Sci,Fac Biol Med & Hlth,Ctr Hlth Informa, Manchester, Lancs, England.-
local.description.affiliation[de Vries, Frank] Southampton Gen Hosp, MRC Epidemiol Lifecourse Unit, Southampton, Hants, England.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.fullcitationAbtahi, Shahab; Burden, Andrea M.; GEUSENS, Piet; van Staa, Tjeerd; VAN DEN BERGH, Joop & de Vries, Frank (2020) The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study. In: Journal of the American Medical Directors Association, 21 (6) , p. 811 -816.-
item.validationecoom 2021-
item.contributorAbtahi, Shahab-
item.contributorBurden, Andrea M.-
item.contributorGEUSENS, Piet-
item.contributorvan Staa, Tjeerd-
item.contributorVAN DEN BERGH, Joop-
item.contributorde Vries, Frank-
crisitem.journal.issn1525-8610-
crisitem.journal.eissn1538-9375-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
The Association of Oral Bisphosphonate .pdf
  Restricted Access		Published version293.39 kBAdobe PDFView/Open    Request a copy
Show simple item record

SCOPUSTM   
Citations

10
checked on Nov 26, 2025

WEB OF SCIENCETM
Citations

10
checked on Dec 1, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.